- About Us
- Nano-Social Network
- Nano Consulting
- My Account
Research and Markets has announced the addition of Jain PharmaBiotech's updated report "Cardiovascular Drug Delivery - Technologies, Markets and Companies" to their extensive offering of medical industry research publications.
Advances in molecular pathophysiology of cardiovascular diseases have brought gene therapy within the realm of possibility as a novel approach to treatment. Gene therapy is not only a sophisticated method of drug delivery, it may in time need drug delivery devices such as catheters for transfer of genes to various parts of the cardiovascular system.
Cardiovascular Drug Delivery - Technologies, Markets and Companies begins by introducing molecular cardiology and examines its relationship to biotechnology and drug delivery systems. Analysis of drug delivery is provided at three levels:
routes of drug delivery
applications to various diseases
Complete sections in Cardiovascular Drug Delivery - Technologies, Markets and Companies are devoted to cell and gene therapies, including antisense and RNA interference, as they are currently at the cutting edge of therapeutics delivery methodology. Various methods of improving systemic administration of drugs for cardiovascular disorders are described including use of nanotechnology.
One of the most exciting areas of biomedical engineering is cell-selective drug delivery, which involves the optimising the therapeutic efficacy of a drug by strictly localizing its pharmacological activity to a pathophysiologically relevant tissue system. Jain PharmaBiotech applies these concepts to targeted drug delivery to the cardiovascular system, while devices for drug delivery to the cardiovascular system are also examined.
The role of drug delivery in various cardiovascular disorders such as myocardial ischemia, hypertension and hypercholesterolemia is discussed, as is cardioprotection. A full chapter is devoted to drug-eluting stents as treatment for restenosis following stenting of coronary arteries.
The treatment of heart disease is being improved with the development of emerging cell-based therapeutic strategies. Cell grafting or mobilizing endogenous cells are potentially, particularly fruitful for heart repair - where the slight capacity for cardiomyocyte proliferation probably contributes to the irreversibility of heart failure. Cell therapy approaches include attempts to reinitiate cardiomyocyte proliferation in the adult, conversion of fibroblasts to contractile myocytes, conversion of bone marrow stem cells into cardiomyocytes, and transplantation of myocytes or other cells into injured myocardium.
The cardiovascular drug delivery markets are estimated for the years 2010 to 2020 on the basis of epidemiology and total markets for cardiovascular therapeutics. Markets for drug-eluting stents are calculated separately.
Key Topics Covered:
Methods for Drug Delivery to the Cardiovascular System
Cell Therapy for Cardiovascular Disorders
Gene Therapy for Cardiovascular Disorders
Markets for Cardiovascular Drug Delivery
Companies involved in Cardiovascular Drug Delivery
Profiles of companies
For more information, please click here
Research and Markets
Laura Wood, Senior Manager
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Copyright © Business WireIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Interviews/Book Reviews/Essays/Reports/Podcasts/Journals/White papers